Related references
Note: Only part of the references are listed.Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature
Karmela Kim Chan et al.
ONCOLOGIST (2020)
Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma
Henry T. Quach et al.
JAMA ONCOLOGY (2019)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy
Leo L. Wang et al.
JAMA DERMATOLOGY (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Jonathan L. Curry et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2017)
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma
Marion Bricout et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
Vincent Sibaud et al.
CURRENT OPINION IN ONCOLOGY (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
Camille Hua et al.
JAMA DERMATOLOGY (2016)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Share Paper
